Publications





Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group.
Ann Surg 2017 Apr 7. Epub 2017 Apr 7.
*Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Center, Department of Surgery, University of Toronto, Toronto, Canada †Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy ‡Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy §Department of Surgery, Institute Curie, Paris, France ¶University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany ||Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands **Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland ††Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom ‡‡Department of Surgery, Institute Gustave Roussy, Villejuif, France §§Department of Surgery, Division of Surgical Oncology, Brigham and Women's Hospital and Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA ¶¶Ontario Institute for Cancer Research, MaRS Center, Toronto, Canada ||||Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. ***Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy †††Department of Surgery, Division of Surgical Oncology, Ohio State University Medical Center, Columbus, OH.



Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group.
Ann Surg 2016 May;263(5):1002-9
*Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy †Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom ‡Department of Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy §Department of Surgery, Institute Gustave Roussy, Villejuif, France ¶Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, and Department of Surgery, University of Toronto, Toronto, Ontario, Canada ||Division of Surgical Oncology & Thoracic Surgery, Mannheim University Hospital, Mannheim, Germany **Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands ††Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland ‡‡Department of Surgery, Division of Surgical Oncology, Brigham and Women's Hospital and Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA §§Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands ¶¶Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy ||||Department of Surgery, Division of Surgical Oncology, Ohio State University Medical Center, Columbus, OH.




Laparoscopic Versus Open Surgery for Gastric Gastrointestinal Stromal Tumors: What Is the Impact on Postoperative Outcome and Oncologic Results?
Ann Surg 2015 Nov;262(5):831-9; discussion 829-40
*Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France †Univ Lille Nord de France, Lille, France ‡Inserm, UMR-S-1172, Jean Pierre Aubert Research Center (JPARC), Team "Mucins, epithelial differentiation and carcinogenesis", Lille, France §SIRIC OncoLille, Lille, France ¶Department of General and Digestive Surgery, Saint-Antoine Hospital, University Pierre & Marie Curie, Paris, France ||Department of Digestive Surgery of Haut-Levêque University Hospital, Bordeaux, France **Department of Biostatistics, University Hospital, Lille, France ††Department of Digestive Surgery, Institut Mutualiste Montsouris, Paris, France ‡‡Department of Digestive Surgery, Croix-Rousse University Hospital, Lyon, France §§Department of Digestive Surgery, Amiens Picardie University Hospital, Amiens, France ¶¶Department of Surgery, Institut Gustave Roussy, Villejuif, France ||||General Surgery, Department of Experimental and Clinical Sciences, University of Brescia, Brescia, Italy ***Department of Digestive Surgery, Dupuytren University Hospital, Limoges, France †††Department of Digestive Surgery, Nantes University Hospital, Nantes, France ‡‡‡Department of Digestive Surgery, Grenoble University Hospital, Grenoble, France §§§Department of Digestive Surgery, Lyon Sud University Hospital, Lyon, France ¶¶¶Department of Surgery of Institut Curie, Paris, France ||||||Department of Digestive Surgery, Saint André University Hospital, Bordeaux, France ****Department of Digestive Surgery, Beaujon University Hospital, Clichy, France ††††Department of Digestive Surgery, Saint Louis University Hospital, Paris, France ‡‡‡‡Department of Digestive Surgery, Pitié-Salpêtrière University Hospital, Paris, France §§§§Department of Digestive Surgery, New Civil University Hospital, Strasbourg, France ¶¶¶¶Department of Digestive Surgery, Cavale Blanche University Hospital, Brest, France ||||||||Department of D

Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival.
Clin Cancer Res 2015 Sep 15;21(18):4194-200. Epub 2015 Apr 15.
Department of Pathology, INSERM U916, Bergonie Institute, Bordeaux, France. Translational Research, Bergonie Institute, Bordeaux, France.


Algorithm for the surgical management of mesenchymal tumors of the perineum in adults.
Dis Colon Rectum 2015 Mar;58(3):304-13
1 Department of Surgical Oncology, Institut Gustave Roussy, Villejuif, France 2 Department of Radiology, Institut Gustave Roussy, Villejuif, France 3 Department of Pathology, Institut Gustave Roussy, Villejuif, France 4 Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France 5 Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France.



Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk.
Ann Surg 2014 May;259(5):973-8
*Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy †Department of Surgery, Institut Gustave Roussy, Villejuif, France ‡Division of General Surgery, Mount Sinai Hospital; Department of Surgical Oncology, Princess Margaret Hospital; and Department of Surgery, University of Toronto, Toronto, Ontario, Canada §Department of Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA ¶Department of Medical Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA ‖Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France **Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
Cancer 2013 Oct 31;119(20):3696-702. Epub 2013 Jul 31.
Sarcoma Service, Department of Surgery, Scientific Institute for Research, Hospitalization, and Health Care (IRCCS) Foundation, National Cancer Institute, Milan, Italy.






Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients.
Clin Sarcoma Res 2012 Sep 5;2(1):11. Epub 2012 Sep 5.
Centre Léon Bérard, Department of Medecine, French Sarcoma Group (GSF-GETO), European Organisation for Research and Treatment of Cancer (EORTC), University Claude Bernard Lyon I, Lyon, France.

Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy.
Cancer Chemother Pharmacol 2012 Feb 19;69(2):357-67. Epub 2011 Jul 19.
Department of Medicine, Sarcoma Unit, Herault Ward, Institut Gustave Roussy, Paris Sud University, 39, rue Camille Desmoulins, 94800 Villejuif cedex, France.






Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma.
Eur J Cancer 2011 Mar 19;47(4):515-9. Epub 2011 Jan 19.
Sarcoma Unit, Herault Ward, Department of Medicine, Institut Gustave Roussy, Université Paris 11, 39 Rue Camille Desmoulins, Villejuif, France.









OF